Blog

bluebird bio Updates Plans for the Year Ahead – Fox Business


Reurope

bluebird bio Updates Plans for the Year Ahead
Fox Business
At the American Society of Hematology (ASH) Annual Meeting in December, Bluebird presented promising data for its updated manufacturing process for LentiGlobin, its gene therapy for transfusion-dependent beta-thalassemia (TDT) and sickle cell disease
Bluebird Bio, Inc. – BLUE – Stock Price Today – ZacksZacks


X0306 4 2018-02-01 0 0001293971 bluebird bio, Inc. BLUE 0001578696 Davidson David C/O BLUEBIRD BIO, INC. 60 …SEC.gov

all 130 news articles »

2018-02-23 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.